Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
Year: 2011
Type: article
Source: Diabetes Obesity and Metabolism
Authors: L. Thomas, R. Grempler, M. Eckhardt, F. Himmelsbach, A. Sauer, T. Klein, P. Eickelmann, M. Mark
Institution: Boehringer Ingelheim (Germany)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2080449229
